Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 1-Year High – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as $96.78 and last traded at $95.35, with a volume of 5603827 shares traded. The stock had previously closed at $91.57.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on DNTH shares. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Stifel Nicolaus set a $120.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Wedbush increased their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Trading Up 4.1%

The company has a market cap of $5.21 billion, a P/E ratio of -23.09 and a beta of 1.18. The company has a 50 day moving average price of $86.46 and a 200-day moving average price of $67.83.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. Equities analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president directly owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Ryan Savitz sold 114,367 shares of the stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 179,121 shares of company stock valued at $15,059,454. 3.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the second quarter worth about $27,000. First Horizon Corp bought a new stake in Dianthus Therapeutics during the 1st quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd bought a new position in Dianthus Therapeutics in the 4th quarter valued at $40,000. Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at $64,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.